Lothar Mϋller

12PUBLICATIONS
77CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 20, 2026
Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

|Jan 05, 2026
Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer.

Julius Keyl, René Hosch, Fabian Hörst

|Nov 18, 2025
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.

Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing

|Jul 30, 2025
Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial.

Alexej Ballhausen, Susanna Swoboda, David Horst

|Mar 18, 2025
Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia.

Valentin Goede, Kirsten Fischer, Sandra Robrecht

|Nov 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Petra Langerbeins, Sandra Robrecht, Pascal Nieper

Pageof 2

Frequent Collaborators

6 joint publications

Dominik Paul Modest

6 joint publications

Arndt Stahler

6 joint publications

Sebastian Stintzing

5 joint publications

Ullrich Graeven